AAV-DJ vector system (AAV-DJ expression system, AAV-DJ packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi (GM) AAV-DJ Vector system is including: 1) AAV-DJ Rep-Cap plasmid (AAV-DJ-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).
You can produce AAV-DJ particle in 293T cell line in high titer using GeneMedi's AAV-DJ Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV-DJ vector has been validated in retina, lung, liver and kidney, with potential applications in tissue-specific gene therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.
Product Description
Cat.NO | Product Name | Organization Type | Price(In USD) | ||
---|---|---|---|---|---|
P-PK15 | AAV-DJ Vector System (Amp resistance) 1. AAV-DJ Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 2388 | ||
P-PK15 | AAV-DJ Vector System (Amp resistance) 1. AAV-DJ Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
P-PK15 | AAV-DJ Vector System (Amp resistance) 1. AAV-DJ Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
P-PK15 | AAV-DJ Vector System (Amp resistance) 1. AAV-DJ Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
P-PK15-Kan | AAV-DJ Vector System (Kan resistance) 1. AAV-DJ Rep-Cap Plasmid (Kan resistance) , ≥10mg 2. AAV Helper Plasmid (Kan resistance) , ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
P-RC15 | AAV-DJ Rep-Cap
Plasmid (Amp resistance)
Size:5ug |
Academic | 1115 | ||
P-RC15 | AAV-DJ Rep-Cap
Plasmid (Amp resistance)
Size:5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
P-RC15 | AAV-DJ Rep-Cap
Plasmid (Amp resistance)
Size:5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
P-RC15 | AAV-DJ Rep-Cap
Plasmid (Amp resistance)
Size:≥10mg |
All | |||
P-RC15-Kan | AAV-DJ Rep-Cap
Plasmid(Kan resistance)
Size:≥10mg |
All | |||
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently. |
|||||
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
Citation
Title | Publication | Date |
---|---|---|
Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor) | Signal Transduction and Targeted Therapy | 2024/1/24 |
Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456 | Signal Transduction and Targeted Therapy | 2023/10/19 |
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation | Molecular Cancer | 2022/4/2 |
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression | Molecular Cancer | 2022/3/18 |
Inhibiting cardiac autophagy suppresses Zika virus replication | Journal of Medical Virology | 2023/1/10 |
Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells | Cell Research | 2020/8/5 |
Neuraminidase 1 promotes renal fibrosis development in male mice | Nature Communications | 2023/3/27 |
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism | Nature Communications | 2023/3/14 |
PSD?93 up?regulates the synaptic activity of corticotropin?releasing hormone neurons in the paraventricular nucleus in depression | Acta Neuropathologica | 2021/9/18 |
Self-assembled ultraflexible probes for long-term neural recordings and neuromodulation | Nature Protocols | 2023/5/29 |
Validation data
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy
Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: Kidney
Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Associated products and services
Products & Service | Products & Service Information |
---|---|
AAV Packaging service | Detail |
Promise-ORF™ viral CDNA library | Detail |
Plasmid DNA Rapid Preparation Service | Detail |